Navigating scalability and consistency in the allogeneic supply chain

Tuesday 09:00 PDT / 12:00 EDT / 16:00 GMT / 17:00 CET

Sponsor

Navigating scalability and consistency in the allogeneic supply chain

In this webinar we will focus on the scalability of donor starting material to support the growth and commercialization of allogeneic therapies. Throughout this discussion we will answer the questions: What are the major gaps currently in the industry? How can we gain a better understanding of what makes an ideal starting material? How do we ensure donor centricity as we further develop allogeneic starting material supply chain processes?

Attend this webinar to learn how to navigate the predicted bottlenecks in the allogeneic supply chain. Familiarize yourself with the speed bumps in the industry to ensure efficiency within your supply chain as you move your therapies into later clinical phases and commercialization.

This webinar will focus on looking ahead at the following challenges:

Future scalability of allo as a starting material
Troubleshooting the quality of a good donor
Varying difficulties found based on the cell therapy type
Differing challenges based on the type of material – ( Ex: CBU, mobilized, vs non-mobilized)

Anne Dircks

Principal Solution Owner at Be The Match BioTherapies

Dean Lee MD PhD

Nationwide Children's Hospital

Dean Anthony Lee, MD, PhD, is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children's Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr. Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine. Dr. Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group.